Europe formulations give Aurobindo a lift

A sales rise of a third in its European Formulations business coupled with growth of almost a tenth in the firm’s US counterpart operation helped Aurobindo Pharma to report group turnover that was 9.3% higher at Rs165 billion (US$2.45 billion) in the Indian firm’s financial year ended 31 March 2018.